We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gen-Probe Licenses HPA Technology to Alnylam
News

Gen-Probe Licenses HPA Technology to Alnylam

Gen-Probe Licenses HPA Technology to Alnylam
News

Gen-Probe Licenses HPA Technology to Alnylam

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gen-Probe Licenses HPA Technology to Alnylam "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gen-Probe Incorporated has announced that it has licensed to Alnylam Pharmaceuticals, Inc. non-exclusive rights to use Gen-Probe's hybridization protection assay (HPA) technology in the development of therapeutic RNA interfering molecules.

"This agreement enables us to generate economic value from our proprietary technologies in an exciting, growing area that is outside our molecular diagnostic focus," said Martin Edelshain, Gen-Probe's vice president of corporate development.

In developing RNAi therapeutics, researchers must be able to monitor the biodistribution of the drugs throughout the body.

Gen-Probe's HPA technology is designed to detect these circulating RNAi molecules. With this technology, a specific DNA probe is labeled with an acridinium ester detector molecule that emits light when the probe hybridizes (binds) with its specified target.

A luminometer detects and measures the light emitted from the reaction, if any. If no light is generated, the target RNAi molecule is not present in the sample.

Advertisement